US health experts to reassess hormone replacement therapy risks
But its use has plummeted in recent years amid concerns over rare side effects, including a potential link to invasive breast cancer.
Food and Drug Administration (FDA) chief Marty Makary, who convened Thursday's meeting of outside experts, has long advocated for HRT, saying its risks have been overstated.
"For decades, hormone replacement therapy for women -- that is estrogen or estrogen plus progesterone -- has helped women alleviate the symptoms of menopause, including hot flashes, dryness, mood swings, weight gain and poor sleep quality, to name a few," he said in a video.
He added that when initiated within a decade of the onset of the transitional period before menopause, HRT may even reduce cognitive decline, the risk of Alzheimer's, and prevent osteoporosis and cardiovascular disease.
Makary blamed the drop in HRT use on a landmark clinical trial, the Women's Health Initiative, which was halted in the early 2000s after it flagged increased risks of breast cancer and stroke. But he said subsequent studies had not replicated the findings on breast cancer.
Critics of the trial argue it was flawed because the participants were too far from menopause, and that the formulations used are now outdated.
Still, the issue remains divisive within the medical community.
The FDA's own warning label for HRT -- which can be administered through various means including orally, through skin patches, or vaginally -- cites risks including endometrial cancer, breast cancer, and life-threatening blood clots.
This week, the American Journal of Physicians published an editorial that found limited benefits and significant harms associated with HRT.
"Menopause is a positive life experience for many women and should not be medicalized," the authors concluded.
The nature of the FDA expert meeting is also unusual. Unlike standard practice before the Trump administration, no agenda was publicly posted.
Several of the named panelists have ties to companies offering menopause treatments or who belong to the advocacy group "Let's Talk Menopause," which receives funding from pharmaceutical companies and campaigns to revise the FDA warning label.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
France 24
4 days ago
- France 24
US authorizes Juul to market vaping products
Juul won the new marketing granting orders (MGO) after submitting more than 110 scientific studies to the agency, the company said in a statement. The decision means Juul can continue to sell products that have been on the US market but in regulatory limbo following earlier actions by the FDA. "Following rigorous evaluation of the data, FDA decided that an MGO for the Juul System was 'appropriate for the protection of public health' –- the standard required by statute for authorization," Juul said. Juul has argued that its vaping products provide a public health benefit by shifting smokers away from combustible tobacco products closely linked to deadly illnesses. But the company has been criticized for its marketing practices, agreeing to pay $438.5 million in a 2022 settlement with 34 US states to resolve accusations of marketing to underage smokers. The FDA's move allows Juul to sell five products in all: the Juul device and capsules for the "Virginia Tobacco" and menthol flavor, each in versions with three or five percent nicotine concentration, said a spokesperson for the US Department of Health and Human Services. The products needed to meet the standard set under a 2009 smoking prevention law showing that the benefits of switching to a potentially less harmful product is "sufficient to outweigh the risks of the product," including to anyone not using tobacco products, the spokesperson said. The applicant submitted data "demonstrating high rates of adults completely switching from cigarettes to either the tobacco- or menthol-flavored Juul products." But the agency's determination "does not mean these tobacco products are safe, nor are they 'FDA approved,'" said the spokesperson, who added that the agency will continue to monitor Juul's compliance with youth marketing restrictions. Juul survived a difficult stretch after the FDA ordered it to halt sales in June 2022 because of health questions, although the decision was adminsistratively suspended by the same agency shortly thereafter. In June 2024, the FDA formally rescinded its June 2022 order, shifting the matter back into "pending" status while a substantive review continued. The FDA's action on Thursday "confirms that these products are now authorized to remain on the market," said a Juul spokesman.
France 24
4 days ago
- France 24
Trump diagnosed with 'benign' vein issue causing leg swelling, White House says
US President Donald Trump has been diagnosed with a chronic but benign vein condition after seeking medical examination for swollen legs, the White House said Thursday. The presidential physician found Trump, 79, has "chronic venous insufficiency" – a condition where damaged leg veins fail to keep blood flowing properly – Press Secretary Karoline Leavitt told reporters, calling it a "benign and common condition". Responding to speculation over recent photos showing bruising on Trump's hand, Leavitt said "this was consistent with minor soft tissue irritation from frequent handshaking and the use of aspirin, which is taken as part of a standard cardiovascular prevention regimen". Trump became the oldest person in history to assume the presidency when he began his second term this January, replacing Democrat Joe Biden, who stepped down at 81. The Republican frequently boasts of his energy levels and the administration recently even posted an image depicting him as Superman. In April, Trump said after undergoing a routine medical check-up that he was in "very good shape". Leavitt's revelations follow viral online discussions about the president's visibly swollen ankles and discoloured right hand. She said he had undergone "a comprehensive examination, including diagnostic vascular studies". "Bilateral lower extremity venous doppler ultrasounds were performed and revealed chronic venous insufficiency, a benign and common condition, particularly in individuals over the age of 70," she said. "Importantly, there was no evidence of deep vein thrombosis or arterial disease," she said. All Trump's test results "were within normal limits," she said and he had a "normal cardiac structure and function, no signs of heart failure, renal impairment or systemic illness". The hand issue, she said, was linked to the aspirin he takes in a "standard" cardiovascular health program.
France 24
4 days ago
- France 24
US health experts reassess hormone replacement therapy risks
HRT is taken to replace estrogen the body stops producing after menopause -- when periods end permanently -- and helps relieve symptoms such as hot flashes, vaginal discomfort, and pain during sex. But its use has plummeted in recent years amid concerns including a potential link to invasive breast cancer. Food and Drug Administration (FDA) chief Marty Makary, who convened Thursday's meeting of outside experts, has long advocated for HRT, saying its risks have been overstated. "For decades, hormone replacement therapy for women -- that is estrogen or estrogen plus progesterone -- has helped women alleviate the symptoms of menopause, including hot flashes, dryness, mood swings, weight gain and poor sleep quality, to name a few," he said in a video ahead of the meeting. He added that when initiated within a decade of the onset of the transitional period before menopause, HRT may even reduce cognitive decline, the risk of Alzheimer's, and prevent osteoporosis and cardiovascular disease. Makary blamed the drop in HRT use on a landmark clinical trial, the Women's Health Initiative, which was halted in the early 2000s after it flagged increased risks of breast cancer and stroke. But he said subsequent studies had not replicated the findings on breast cancer. "The many benefits of hormone therapy were ignored as it was seen as a carcinogen. Prescriptions for hormone replacement therapy plummeted in the United States, women flushed their pills down the toilet," he said Thursday. "Fifty million plus women have not been offered the incredible potential health benefits of hormone replacement therapy because of medical dogma," he added, including his own mother, who suffered multiple bone fractures in her older life. Critics of the trial argue it was flawed because the participants were too far from menopause, when risks are elevated and benefits limited, and that the formulations used are now outdated. Label changes Still, the issue remains divisive within the medical community. The FDA's own warning label for HRT -- which can be administered through various means including orally, through skin patches, or vaginally -- cites risks including endometrial cancer, breast cancer, and life-threatening blood clots. This week, the American Family Physician journal published an editorial that found limited benefits and significant harms associated with HRT. "Menopause is a positive life experience for many women and should not be medicalized," the authors concluded. The nature of the FDA expert meeting is also unusual. Unlike standard practice before the Trump administration, no agenda was publicly posted. Several of the named panelists have ties to companies offering menopause treatments or who belong to the advocacy group "Let's Talk Menopause," which receives funding from pharmaceutical companies and campaigns to revise the FDA warning label.
